These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25251804)

  • 21. Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.
    Vreede CL; Berkhout MC; Sprij AJ; Fokkens WJ; Heijerman HG
    J Cyst Fibros; 2015 May; 14(3):412-3. PubMed ID: 25169789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tezacaftor/Ivacaftor (Symdeko) for cystic fibrosis.
    Med Lett Drugs Ther; 2018 Oct; 60(1558):174-176. PubMed ID: 30335045
    [No Abstract]   [Full Text] [Related]  

  • 23. A safety evaluation of ivacaftor for the treatment of cystic fibrosis.
    McColley SA
    Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273
    [No Abstract]   [Full Text] [Related]  

  • 25. The use of ivacaftor in an adult with severe lung disease due to cystic fibrosis (ΔF508/G551D).
    Polenakovik HM; Sanville B
    J Cyst Fibros; 2013 Sep; 12(5):530-1. PubMed ID: 23313410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of ivacaftor on nonpulmonary outcomes in individuals with cystic fibrosis, heterozygous for a S1251N mutation.
    Burghard MM; Berkers GG; Ghijsen SS; Hollander-Kraaijeveld FF; de Winter-de Groot KK; van der Ent CK; Heijerman HH; Takken TT; Hulzebos HE
    Pediatr Pulmonol; 2020 Jun; 55(6):1400-1405. PubMed ID: 32233113
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.
    Bratcher PE; Rowe SM; Reeves G; Roberts T; Szul T; Harris WT; Tirouvanziam R; Gaggar A
    J Cyst Fibros; 2016 Jan; 15(1):67-73. PubMed ID: 25769931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Ivacaftor in Severe Cystic Fibrosis in a Patient With the R117H Mutation.
    Ronan NJ; Fleming C; O'Callaghan G; Maher MM; Murphy DM; Plant BJ
    Chest; 2015 Sep; 148(3):e72-e75. PubMed ID: 26324139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation.
    Hebestreit H; Sauer-Heilborn A; Fischer R; Käding M; Mainz JG
    J Cyst Fibros; 2013 Dec; 12(6):599-603. PubMed ID: 23757359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics.
    Fohner AE; McDonagh EM; Clancy JP; Whirl Carrillo M; Altman RB; Klein TE
    Pharmacogenet Genomics; 2017 Jan; 27(1):39-42. PubMed ID: 27636560
    [No Abstract]   [Full Text] [Related]  

  • 31. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
    [No Abstract]   [Full Text] [Related]  

  • 32. Improvement of hepatic steatosis in cystic fibrosis with ivacaftor therapy.
    Hayes D; Warren PS; McCoy KS; Sheikh SI
    J Pediatr Gastroenterol Nutr; 2015 May; 60(5):578-9. PubMed ID: 25688481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ivacaftor. Uncertain harm-benefit balance.
    Prescrire Int; 2013 Oct; 22(142):229-31. PubMed ID: 24298579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ivacaftor potentiation of multiple CFTR channels with gating mutations.
    Yu H; Burton B; Huang CJ; Worley J; Cao D; Johnson JP; Urrutia A; Joubran J; Seepersaud S; Sussky K; Hoffman BJ; Van Goor F
    J Cyst Fibros; 2012 May; 11(3):237-45. PubMed ID: 22293084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
    Antoniu SA
    Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement in bronchiectasis on CT imaging in a pediatric patient with cystic fibrosis on ivacaftor therapy.
    Hayes D; Long FR; McCoy KS; Sheikh SI
    Respiration; 2014; 88(4):345. PubMed ID: 25171465
    [No Abstract]   [Full Text] [Related]  

  • 37. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
    Van Goor F; Yu H; Burton B; Hoffman BJ
    J Cyst Fibros; 2014 Jan; 13(1):29-36. PubMed ID: 23891399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cystic fibrosis in an era of genomically guided therapy.
    Barrett PM; Alagely A; Topol EJ
    Hum Mol Genet; 2012 Oct; 21(R1):R66-71. PubMed ID: 22914736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A successful uncomplicated CF pregnancy while remaining on Ivacaftor.
    Kaminski R; Nazareth D
    J Cyst Fibros; 2016 Jan; 15(1):133-4. PubMed ID: 26698017
    [No Abstract]   [Full Text] [Related]  

  • 40. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.
    Suthoff ED; Bonafede M; Limone B; O'Callaghan L; Sawicki GS; Wagener JS
    J Med Econ; 2016 Sep; 19(9):845-51. PubMed ID: 27074519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.